Rocket Lab (NASDAQ: RKLB) delivered a quarter that fundamentally reframes the investment case for the commercial space company.
Revenue hit a record $234.07 million in Q2 FY2026, up 61.99% year over year and narrowly beating the $230.94 million consensus estimate.
GAAP EPS of -$0.08 missed expectations, weighed down by $8.58 million in acquisition transaction costs tied to recent deal activity.
The backlog figure is what stands out most, reaching $2.36 billion, up 137% year over year, with more than $1 billion in new contracts already signed in Q3.
Q3 revenue guidance of $250 million to $265 million sets up what would be yet another record quarter for the company.
Our price target for Rocket Lab sits at $120.55, implying upside of 50.61% from the current price of $80.04, with a buy recommendation at 50% confidence given execution risk on Neutron and multi-acquisition integration.
The acquisition of Iridium is the centerpiece of the bull thesis, transforming Rocket Lab into a vertically integrated space communications platform with global reach.
CEO Peter Beck described the strategic vision directly: “these moves position Rocket Lab to accelerate our future into space applications by becoming a self-launching, tier-1 space power that will deliver critical communications capability to millions of users worldwide.”
Adding further revenue visibility, Rocket Lab secured a $397 million U.S. Space Force Flatellite contract, marking the first geostationary satellite production for the U.S. government.
RKLB shares are up 13.64% over the past week and 79.1% over the past year, though the stock still trades well below its 52-week high of $151.
The bull-case price target of $158.06, representing roughly a 97% return, is achievable if Neutron ships on schedule in Q4 2026 and the Iridium deal closes without complications.
Execution risk and dilution pressure form the core of the bear scenario, with Rocket Lab having raised $1.53 billion via ATM in H1 2026 and Q3 weighted-share count guided to 641 million shares.
CEO Beck sold shares across July 6 through July 8, 2026, at prices between $81.59 and $101.57, transactions that appear consistent with systematic diversification at elevated valuations.
The bear-case target of $94.53 assumes Neutron slips its schedule and Iridium integration continues to drag on GAAP losses through 2027.
Comparing RKLB to peers offers useful context: AST SpaceMobile (NASDAQ: ASTS) carries a market cap of roughly $20.5 billion on Q2 revenue of just $31.5 million, a fraction of Rocket Lab’s top line.
Planet Labs (NYSE: PL) trades at a market cap of roughly $7.9 billion on FY2027 revenue guidance of $425 million to $441 million and adjusted EBITDA profitability, and it already generates positive cash flow.
On a price-to-sales basis, RKLB commands a steep premium at 76x trailing twelve-month sales, a multiple that rests on launch monopoly economics and Iridium optionality rather than current fundamentals.
Looking further out, the model projects RKLB reaching $155 in 2027, $190 in 2028, $220 in 2029, and $246.81 by 2030, assuming Neutron enters commercial service and Iridium integrates cleanly.
Significant upside or downside remains tied directly to the outcome of Neutron’s inaugural launch, which represents the single highest-stakes catalyst in the company’s near-term roadmap.
The scale of the backlog, a record $2.36 billion combined with over $1 billion in Q3 signings, gives Rocket Lab multi-year revenue visibility that few peers in the commercial space sector can match.
